This site is intended for healthcare professionals

Novartis Kymriah pivotal ELARA trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma.

Read time: 1 mins
Last updated:3rd Jun 2021
Published:3rd Jun 2021
Novartis announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) .
Condition: Follicular Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest